TRANSCODE THERAPEUTICS, INC.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers

TTX-MC138

Lead Candidate: TTX-MC138

Small, non-coding strands of RNA have been identified as a significant player in the pathology of cancer. One of the first miRNAs to be shown as having aberrant expression in cancer was miR-10b. Since the inaugural study on miR-10b, its role as a metastasis promoting factor has been extensively validated, as a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon, glioblastomas, and others. To date, more than 100 studies have been completed on miR-10b and metastasis across 18 cancer types.

​TransCode’s lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b (miR-10b) and eliminate metastasis. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. ​
Picture
Picture

​Pre-Clinical Evidence

     Metastatic Breast Cancer

In multiple pre-clinical models of triple-negative breast cancer (TNBC), treatment with low-dose chemotherapy and TTX-MC138 eliminated pre-existing local metastases in 100% of treated animals representative of stage II/III metastatic cancer. In models representative of stage IV metastatic cancer, treatment with low-dose chemotherapy and TTX-MC138 resulted in elimination of distant metastases in 65% of animals treated.
​Notably, no recurrence of metastases occurred following TTX-MC138 treatment cessation. 
Picture
Picture
Sources: Yoo B, et al. Cancer Res. 2015;75(20):4407-4415; Yoo B, et al. Sci Rep. 2017;7:45060; Figure 11 in S-1 Preclinical results of TTX-MC138 in models of metastatic breast cancer.

    Pancreatic Cancer

Positive preclinical results achieved with its lead candidate therapeutic, TTX-MC138, in pancreatic adenocarcinoma. 
​
TTX-MC138, applied as monotherapy, in a murine model of pancreatic adenocarcinoma, showed that forty percent (40%) of animals treated had complete responses, defined as complete regression of disease and long-term survival without recurrence.
Survival
Picture
Target Inhibiton
Picture
qRT-PCR shows target engagement and the potential to use miR-10b expression in serum as a  biomarker of therapeutic success

Clinical Path Forward

A first in human Phase O study with TTX-MC138 is planned for 1Q of 2023, and is expected to be followed by Phase I/II.

More About TTX-MC138

​For additional information about our groundbreaking lead investigational candidate, TTX-MC138, see the information sheet below.
Picture
Download
Preview

Other Candidates

Learn more about TransCode's other therapeutic candidates.
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

About

About
leadership

Partnering
​Careers     

Focus

Focus

Science

Science
​Resources

Pipeline

PIPELINE
TTX-MC138
​OTHER CANDIDATES

Contact/Support

Contact
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2022.​ ALL RIGHTS RESERVED.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers